Over 25 Prothenians attended the 16th annual Clinical Trials on Alzheimer’s Disease (CTAD) meeting in October in Boston, Massachusetts. As always, it was inspiring to join experts in the space to discuss the latest advances in Alzheimer’s disease R&D as we work toward a shared goal of delivering better treatments to patients.
Throughout the year we’ve seen exciting data from many different companies and important regulatory updates from the FDA. The energy at the CTAD conference was reflective of this optimism, and the meeting proved to be rich in the discussion of many perspectives that are driving this ground-breaking innovation on topics like biomarkers, new investigational treatment options and diversity within the Alzheimer’s disease community.
Hear from our Chief Medical Officer, Hideki Garren, M.D., Ph.D., on the future of Alzheimer’s disease treatments here:
We are excited to be at #CTAD23 in Boston today, discussing the latest data and perspectives that are driving innovation for people affected by #Alzheimers disease. Hear from our Chief Medical Officer, Hideki Garren, on the future of Alzheimer’s disease treatments. pic.twitter.com/DvnzzjhY0U
— Prothena Corporation (@ProthenaCorp) October 26, 2023
Emerging themes from CTAD were around prioritizing earlier treatment, which may have a greater impact in slowing disease progression, as well as targeting other key proteins, in addition to amyloid beta. Hear from our Chief Executive Officer, Gene Kinney, Ph.D., on progress in the field here:
As we wrap up an incredible week at #CTAD23, we’re energized by many key learnings that have illuminated the path forward in #Alzheimers disease treatment and research. Hear from our CEO, Gene Kinney, on his thoughts around progress in the field. pic.twitter.com/tHcXPAfJRT
— Prothena Corporation (@ProthenaCorp) October 27, 2023
As Gene has noted in the past, “it takes a village,” and we are proud to be a part of that village. We continue to advance programs across our pipeline to address devastating neurological diseases caused by protein dysregulation which affect millions of people and their families worldwide. Given our expertise in developing therapeutic approaches that target misfolded proteins to achieve clinical benefit, we remain steadfast in our intent to deliver patient-centric solutions for the Alzheimer’s disease community.